About the Authors
MDC declares that he is a retired employee of the pharmaceutical company Eli Lilly and Company, and also owns Lilly stock. PBC declares that he is a general partner of a private equity fund that buys potential medicines in development and develops them further, usually to regulatory approval. He is the retired head of Science and Technology for Pfizer and has stock options as well as stock in the company. He also receives retirement benefits and deferred compensation. He is a board member of Cbio, a biotech company based in Australia, for which he receives remuneration. He is advisor to the president for an information technology firm called Global Edit in New York City, for which he will receive future equity if the company is successful. Payments are donated to charities of his choice. He is a chair or a member of the following Boards: Joyce Theater (New York City), Georgetown University Board of Regents (Washington, D. C.), New York Academy of Sciences (New York City), C-Path Institute (Tuscon, Arizona), Institute of Medicine Drug Forum (Washington, D. C.), and International Partnership for Microbicides (Washington, D. C.). He receives no compensation, directly or indirectly, for any of these positions. SD is Chief Innovation Officer at Quintiles, which has contracts with all of the major pharmaceutical firms. The remaining authors declare that they have no competing interests.
This paper began as a synthesis of the contributions of each of the 15 named authors to the Workshop on the Ancillary-Care Obligations of Medical Researchers Working in Developing Countries, held at Georgetown University, Washington, D. C., October 20–22, 2006. Working from the authors' PowerPoint slides and/or from notes on their contributions and in consultation with C. Grady and R. Lie, H. Richardson produced the drafts of this article. Each of the 15 coauthors participated in the rounds of revision, of which there were several.